Canadian Respiratory Journal · 2019 · 17 citations · 19 references
Life SciencesImmunologyPharmacologyClinical ImmunologyImmunopharmacologyImmunotherapyAsthma PharmacotherapyEosinophilic DisordersMucosal InflammationPulmonary InflammationAirway Inflammation ModulationAnti-interleukin 5 TherapyEpithelial-derived CytokinesExhaled Nitric OxideHumanized Monoclonal AntibodiesInterleukin-5 Targeted TherapyNitric OxidePharmacotherapy For Eosinophilic Asthma
The bronchial epithelium has continuous contact with environmental agents initiating and maintaining airway type 2 inflammation in asthma. However, there is a lack of data on whether reduced airway eosinophilic inflammation can affect the production of epithelial-derived mediators, such as interleukin-25 (IL-25) and thymic stromal lymphopoietin (TSLP). The aim of this study was to investigate the changes in serum levels of IL-25 and TSLP after a single dose of mepolizumab, a humanized monoclonal antibody to interleukin-5 (IL-5), in patients with severe non-allergic eosinophilic asthma (SNEA). We examined 9 SNEA patients before and four weeks after administration of 100 mg mepolizumab subcutaneously. The fractional exhaled nitric oxide (FeNO) level was analysed using an electrochemical assay (NIOX VERO®, Circassia, UK). Serum IL-25 and TSLP levels were measured by ELISA. Four weeks after the single dose of mepolizumab, blood eosinophil count significantly decreased from 0.55 ± 0.20 × 10 9 /l to 0.14 ± 0.04 × 10 9 /l (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:math>) and FEV 1 increased from 2.1 ± 0.5 l (65.4 ± 8.8% of predicted) to 2.6 ± 0.4 l (76.4 ± 9.1% of predicted) (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M2"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.04</mml:mn></mml:mrow></mml:math>), while FeNO level has not changed (32.3 ± 8.4 vs 42.9 ± 12.6 ppb). Serum IL-25 level significantly decreased from 48.0 ± 17.2 pg/mL to 34.8 ± 17.1 pg/mL (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math>) with same tendency in TSLP level: from 359.8 ± 71.3 pg/mL to 275.6 ± 47.8 pg/mL (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M4"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.02</mml:mn></mml:mrow></mml:math>). It has also been noticed a significant relation between changes in the blood eosinophil count and serum IL-25 level ( r = 0.81, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.008</mml:mn></mml:mrow></mml:math>), as well as between changes in serum IL-25 and TSLP levels ( r = 0.93, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M6"><mml:mrow><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.004</mml:mn></mml:mrow></mml:math>) after a single dose of mepolizumab. Thus, anti-IL-5 treatment with mepolizumab might diminish the production of bronchial epithelial-derived cytokines IL-25 and TSLP in patients with SNEA which is potentially related to reduced eosinophilic inflammation. This trial is registered in ClinicalTrial.gov with identifier NCT03388359 .
19
Raed A. Dweik, Peter B. Boggs, Serpil C. Erzurum et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 2.5K citations
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Héctor Ortega, Mark C. Liu, Ian Pavord et al. · New England Journal of Medicine · 2014 · 2.3K citations · Full text
Jean Bousquet, Eva Mantzouranis, Álvaro A. Cruz et al. · Journal of Allergy and Clinical Immunology · 2010 · 739 citations · Full text
Geoffrey Chupp, Eric Bradford, Frank C. Albers et al. · The Lancet Respiratory Medicine · 2017 · 590 citations